Proved undeveloped reserves

Energy Term

Proved undeveloped reserves is a term used in the energy industry to refer to the estimated amount of oil and gas reserves that are located in a known reservoir but have not yet been developed due to technical or economic constraints. These reserves are considered to be potentially recoverable with existing technology and at current economic conditions.

Proved undeveloped reserves are typically estimated based on geological data, exploration drilling, and other technical assessments. They are categorized as a subset of proved reserves, which also include developed and producing reserves. Proved reserves are the estimated amount of oil and gas reserves that can be recovered with a high degree of certainty, typically defined as a 90% or higher probability.

In the energy industry, proved undeveloped reserves are important because they represent a potential source of future production and revenue for exploration and production companies. However, the development of these reserves requires significant capital expenditures and investment in infrastructure, including drilling rigs, pipelines, and processing facilities.

The classification of reserves, including proved undeveloped reserves, is also important for regulatory purposes, particularly for companies that are publicly traded. These companies are required to report their reserves to the Securities and Exchange Commission and other regulatory bodies, and different categories of reserves can impact the company*s financial statements and valuation.

Overall, proved undeveloped reserves play an important role in the energy industry by providing a potential source of future production and revenue, as well as influencing regulatory reporting and valuation for energy companies.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P